{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:24:56Z","timestamp":1787030696419,"version":"build-2736575974"},"reference-count":15,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.3892\/mco.2016.866","type":"journal-article","created":{"date-parts":[[2016,4,20]],"date-time":"2016-04-20T03:56:35Z","timestamp":1461124595000},"page":"23-26","source":"Crossref","is-referenced-by-count":8,"title":["Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment"],"prefix":"10.3892","volume":"5","author":[{"given":"ELEFTHERIA","family":"HATZIMICHAEL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KONSTANTINOS","family":"LAGOS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AMALIA","family":"VASSOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DORA","family":"GOUGOPOULOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALEXANDRA","family":"PAPOUDOU-BAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EVANGELOS","family":"BRIASOULIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,4,20]]},"reference":[{"key":"key20180107150509_b1-mco-0-0-866","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","article-title":"Unraveling the molecular pathophysiology of myelodysplastic syndromes","volume":"29","author":"Bejar","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107150509_b2-mco-0-0-866","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3324\/haematol.13377","article-title":"Myelodysplastic syndrome with isolated 5q deletion (5q-syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis","volume":"93","author":"Cazzola","year":"2008","journal-title":"Haematologica"},{"key":"key20180107150509_b3-mco-0-0-866","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180107150509_b4-mco-0-0-866","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"key20180107150509_b5-mco-0-0-866","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders","volume":"106","author":"Scott","year":"2005","journal-title":"Blood"},{"key":"key20180107150509_b6-mco-0-0-866","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/sj.leu.2404215","article-title":"The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow","volume":"20","author":"Ingram","year":"2006","journal-title":"Leukemia"},{"key":"key20180107150509_b7-mco-0-0-866","author":"Swerdlow","year":"2008","journal-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues"},{"key":"key20180107150509_b8-mco-0-0-866","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"key20180107150509_b9-mco-0-0-866","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3109\/10428194.2010.506567","article-title":"Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation","volume":"51","author":"Azaceta","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"key20180107150509_b10-mco-0-0-866","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.leukres.2011.06.008","article-title":"Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation","volume":"35","author":"Nomdedeu","year":"2011","journal-title":"Leuk Res"},{"key":"key20180107150509_b11-mco-0-0-866","first-page":"1043","article-title":"Myelodysplastic disorders carrying both isolated del(5q) and JAK2 (V617F) mutation: Concise review, with focus on lenalidomide therapy","volume":"7","author":"Musto","year":"2014","journal-title":"Onco Targets Ther"},{"key":"key20180107150509_b12-mco-0-0-866","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.leukres.2009.09.016","article-title":"JAK2 (V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones","volume":"34","author":"Sokol","year":"2010","journal-title":"Leuk Res"},{"key":"key20180107150509_b13-mco-0-0-866","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00277-008-0449-0","article-title":"Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes","volume":"87","author":"Giagounidis","year":"2008","journal-title":"Ann Hematol"},{"key":"key20180107150509_b14-mco-0-0-866","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3324\/haematol.2011.045914","article-title":"Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the groupe francophone des myelodysplasies","volume":"97","author":"Ad\u00e8s","year":"2012","journal-title":"Haematologica"},{"key":"key20180107150509_b15-mco-0-0-866","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000362643","article-title":"Long-term response in a patient with del(5q) myelodysplastic syndrome who discontinued lenalidomide and obtained a good response and tolerance to rechallenge","volume":"7","author":"Pisani","year":"2014","journal-title":"Case Rep Oncol"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mco.2016.866\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T18:09:10Z","timestamp":1600452550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mco.2016.866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,20]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,4,20]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.3892\/mco.2016.866"],"URL":"https:\/\/doi.org\/10.3892\/mco.2016.866","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,20]]}}}